Literature summary for 3.4.21.77 extracted from

van den Bergh, R.C.; Roemeling, S.; Roobol, M.J.; Wolters, T.; Schroeder, F.H.; Bangma, C.H.
Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review (2008), Eur. Urol., 54, 505-516.

Search for more literature for 3.4.21.77

Application

Application	Comment	Organism
medicine	kinetics of prostate-specific antigen are indicative of tumour progression and are therefore used in clinical decision-making in men on active surveillance for early prostate cancer. A high prostate-specific antigen velocity or short prostate-specific antigen doubling time are related with an unfavourable outcome and should lead to performing an additional prostate biopsy or to deferred radical treatment during follow-up of active surveillance. A low prostate-specific antigen velocity or a long prostate-specific antigen doubling time is associated with a nonaggressive course of the disease and may justify a more conservative attitude. A prostate-specific antigen doubling time more than 10 years, a static course of the prostate-specific antigen values, or a negative prostate-specific antigen doubling time are generally associated with a good prognosis. A prostate-specific antigen doubling time of less than 3-4 years should lead to the advice to switch to radical treatment	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
serum	-	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
prostate-specific antigen	-	Homo sapiens
PSA	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)